Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Denosumab (XGEVA) for hypercalcaemia of malignancy – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Denosumab is a drug to treat hypercalcaemia of malignancy. Hypercalcaemia is a condition in which you have too much calcium in your blood and is quite common in people who have cancer. Calcium performs important functions, such as helping to keep your bones healthy. However, too much of it can cause problems and symptoms that include sickness, constipation, confusion, and high blood pressure. Denosumab is taken as an injection under the skin and is designed to reduce the amount of calcium in the blood. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Denosumab; Humans; Hypercalcemia; Neoplasms, Second Primary Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016001026 Date abstract record published 11/10/2016 |